Novartis will cut 550 full-time jobs at a facility in Switzerland by the end of 2027. The cuts come as the pharma company is ending production of tablets, capsules, and sterile medicine packaging at a plant in Stein, Switzerland.
All entries for: Novartis
April 10, 2025
Novartis
Layoffs
Basel, Switzerland
10,001-50,000 employees
Novartis disclosed two layoffs, with the largest one affecting 427 employees at its U.S. headquarters in East Hanover, New Jersey, and 34 employees in San Diego.
Disease Area: Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
March 19, 2025
Novartis - San Diego
Layoffs
San Diego, CA
50,001+ employees
Novartis is putting 34 more jobs on the chopping block, this time affecting employees at its Campus Point manufacturing facility in San Diego, California. According to the WARN notice posted March 13, the layoffs are in connection with the site’s closure and will be effective on June 27.
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
May 19, 2023
Novartis
Discontinued Drug, Discontinued Research
Basel, Switzerland
10,001-50,000 employees
“In an interview with Barron’s, Narasimhan said some of the programs which Novartis discontinued were cancer drugs in early-stage trials.
“We saw assets that were noncompetitive, or we thought might be unduly affected by IRA,” Narasimhan said.
The CEO said “a few” of the cancer drugs being dropped from Novartis’s pipeline were discontinued because of price negotiations.
The drugs that were dropped were “in areas where we didn’t think we could do a development plan that would allow us to successfully get the drug in patients, and fully developed across the range of indications within nine years,” Narasimhan said. They were in cancers particularly affecting the elderly, given that Medicare treats adults aged 65 and older.”
2 Discontinued Drugs: unnamed cancer drugs
2 Discontinued Research Programs
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
January 20, 2023
Novartis
Negative Outlook
Basel, Switzerland
10,001-50,000 employees
“U.S. government plans to rein in drug prices could discourage work in some of Novartis’s most promising areas of research, the Swiss drugmaker warned on Friday, urging Washington to rethink the “unintended” effects of its new rules… Lawmakers’ intention may be to favour sophisticated biologics over seemingly more conventional chemical drugs, but some of the most promising new treatment approaches belong to the latter group, said Victor Bulto, Novartis’s President Innovative Medicines for the U.S. market. “The most concerning piece in that legislation for us is the price setting after nine years for small molecules and 13 years for biologics,” Bulto told Reuters.”
Disease Area: Multiple, Oncology
Drug Type: Small Molecule